BACKGROUND: Previously, we have shown that withdrawal of fall-risk-increasing drugs (FRIDs) as a single intervention reduces falls incidence. Improvement of mobility may be an important factor in this finding and we therefore tested whether mobility tests improved after FRID withdrawal. METHODS: In a prospective cohort study of 137 geriatric outpatients (age 77.7 +/- 5.7 years), FRIDs were withdrawn in all fallers, if possible, between April 2003 and November 2004. All patients underwent mobility testing at baseline, including a 10m walking test (WT), Timed 'Up & Go' Test (TUGT), Functional Reach Test (FRT), isometric quadriceps femoris muscle strength and a body sway test. Retesting occurred at a mean follow-up of 6.7 months. The effect of FRID withdrawal (discontinuation or dose reduction) on test outcomes was calculated using both multivariate linear and binary logistic regression analyses. RESULTS: In the group of fallers with FRID withdrawal all mobility tests improved, as opposed to non-fallers and fallers without FRID withdrawal. After adjustment for confounders, the odds ratio of no improvement was 0.14 (95% CI 0.03, 0.59) for the TUGT, 0.19 (95% CI 0.04, 0.86) for the 10m WT, 0.48 (95% CI 0.14, 1.57) for the FRT, 0.46 (95% CI 0.14, 1.48) for the quadriceps strength test and 0.49 (95% CI 0.15, 1.62) for the body sway test. CONCLUSION: The results of this study suggest that FRID withdrawal may be effective as a single intervention in a geriatric setting. In addition to reducing falls (as shown in our previous study), FRID withdrawal significantly improved 10m WT and TUGT results over a mean follow-up period of 6.7 months. These tests may therefore be useful tools for monitoring the clinical effect of FRID withdrawal.
BACKGROUND: Previously, we have shown that withdrawal of fall-risk-increasing drugs (FRIDs) as a single intervention reduces falls incidence. Improvement of mobility may be an important factor in this finding and we therefore tested whether mobility tests improved after FRID withdrawal. METHODS: In a prospective cohort study of 137 geriatric outpatients (age 77.7 +/- 5.7 years), FRIDs were withdrawn in all fallers, if possible, between April 2003 and November 2004. All patients underwent mobility testing at baseline, including a 10m walking test (WT), Timed 'Up & Go' Test (TUGT), Functional Reach Test (FRT), isometric quadriceps femoris muscle strength and a body sway test. Retesting occurred at a mean follow-up of 6.7 months. The effect of FRID withdrawal (discontinuation or dose reduction) on test outcomes was calculated using both multivariate linear and binary logistic regression analyses. RESULTS: In the group of fallers with FRID withdrawal all mobility tests improved, as opposed to non-fallers and fallers without FRID withdrawal. After adjustment for confounders, the odds ratio of no improvement was 0.14 (95% CI 0.03, 0.59) for the TUGT, 0.19 (95% CI 0.04, 0.86) for the 10m WT, 0.48 (95% CI 0.14, 1.57) for the FRT, 0.46 (95% CI 0.14, 1.48) for the quadriceps strength test and 0.49 (95% CI 0.15, 1.62) for the body sway test. CONCLUSION: The results of this study suggest that FRID withdrawal may be effective as a single intervention in a geriatric setting. In addition to reducing falls (as shown in our previous study), FRID withdrawal significantly improved 10m WT and TUGT results over a mean follow-up period of 6.7 months. These tests may therefore be useful tools for monitoring the clinical effect of FRID withdrawal.
Authors: Nathalie van der Velde; Bruno H Ch Stricker; Huib A P Pols; Tischa J M van der Cammen Journal: Br J Clin Pharmacol Date: 2006-08-30 Impact factor: 4.335
Authors: Ulrike Sommeregger; Bernhard Iglseder; Birgit Böhmdorfer; Ursula Benvenuti-Falger; Peter Dovjak; Monika Lechleitner; Ronald Otto; Regina E Roller; Markus Gosch Journal: Wien Med Wochenschr Date: 2010-06
Authors: Maartje H de Groot; Jos P C M van Campen; Marije A Moek; Linda R Tulner; Jos H Beijnen; Claudine J C Lamoth Journal: Drugs Aging Date: 2013-11 Impact factor: 3.923
Authors: Alexander Bennett; Danijela Gnjidic; Mark Gillett; Peter Carroll; Slade Matthews; Kristina Johnell; Johan Fastbom; Sarah Hilmer Journal: Drugs Aging Date: 2014-03 Impact factor: 3.923
Authors: Eric Anson; Elizabeth Thompson; Brian L Odle; John Jeka; Zachary F Walls; Peter C Panus Journal: J Geriatr Phys Ther Date: 2018 Oct/Dec Impact factor: 3.381
Authors: Angela Chalé-Rush; Jack M Guralnik; Michael P Walkup; Michael E Miller; W Jack Rejeski; Jeffrey A Katula; Abby C King; Nancy W Glynn; Todd M Manini; Steven N Blair; Roger A Fielding Journal: J Am Geriatr Soc Date: 2010-08-24 Impact factor: 5.562
Authors: Marjan Askari; Saied Eslami; Alice C Scheffer; Stephanie Medlock; Sophia E de Rooij; Nathalie van der Velde; Ameen Abu-Hanna Journal: Drugs Aging Date: 2013-10 Impact factor: 3.923
Authors: Allen R Huang; Louise Mallet; Christian M Rochefort; Tewodros Eguale; David L Buckeridge; Robyn Tamblyn Journal: Drugs Aging Date: 2012-05-01 Impact factor: 3.923
Authors: Amy T Page; Rhonda M Clifford; Kathleen Potter; Darren Schwartz; Christopher D Etherton-Beer Journal: Br J Clin Pharmacol Date: 2016-06-13 Impact factor: 4.335